Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.

Kleiblová P, Stolařová L, Křížová K, Lhota F, Hojný J, Zemánková P, Havránek O, Vočka M, Černá M, Lhotová K, Borecká M, Janatová M, Soukupová J, Ševčík J, Zimovjanová M, Kotlas J, Panczak A, Veselá K, Červenková J, Schneiderová M, Burócziová M, Burdová K, Stránecký V, Foretová L, Macháčková E, Tavandzis S, Kmoch S, Macůrek L, Kleibl Z.

Klin Onkol. 2019 Summer;32(Supplementum2):36-50. doi: 10.14735/amko2019S36.

PMID:
31409080
2.

Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers.

Vocka M, Zimovjanova M, Bielcikova Z, Tesarova P, Petruzelka L, Mateju M, Krizova L, Kotlas J, Soukupova J, Janatova M, Zemankova P, Kleiblova P, Novotny J, Konopasek B, Chodacka M, Brychta M, Sochor M, Smejkalova-Musilova D, Cmejlova V, Kozevnikovova R, Miskarova L, Argalacsova S, Stolarova L, Lhotova K, Borecka M, Kleibl Z.

Cancers (Basel). 2019 May 28;11(6). pii: E738. doi: 10.3390/cancers11060738.

3.

Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.

Kleiblova P, Stolarova L, Krizova K, Lhota F, Hojny J, Zemankova P, Havranek O, Vocka M, Cerna M, Lhotova K, Borecka M, Janatova M, Soukupova J, Sevcik J, Zimovjanova M, Kotlas J, Panczak A, Vesela K, Cervenkova J, Schneiderova M, Burocziova M, Burdova K, Stranecky V, Foretova L, Machackova E, Tavandzis S, Kmoch S, Macurek L, Kleibl Z.

Int J Cancer. 2019 Oct 1;145(7):1782-1797. doi: 10.1002/ijc.32385. Epub 2019 May 20.

PMID:
31050813
4.

[Is preoperative bone scintigraphy in early stage of breast cancer T1N0 indicated and meaningful?].

Žaloudík J, Skovajsová M, Česlarová K, Bieberová L, Hussarová L, Zimovjanová M, Petruželka L.

Klin Onkol. 2013;26(6):443-7. Czech.

PMID:
24320594
5.

The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer.

Janatova M, Kleibl Z, Stribrna J, Panczak A, Vesela K, Zimovjanova M, Kleiblova P, Dundr P, Soukupova J, Pohlreich P.

Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2323-32. doi: 10.1158/1055-9965.EPI-13-0745-T. Epub 2013 Oct 17.

6.

[Oxidative stress after anthracycline therapy in patients with solid tumors].

Kocik M, Zimovjanova M, Petruzelka L, Kodydkova J, Vavrova L, Zak A.

Cas Lek Cesk. 2012;151(10):463-7. Czech.

PMID:
23256630
7.

[Breast reconstruction by autologous fat transfer].

Mestak O, Zimovjanová M.

Rozhl Chir. 2012 Jul;91(7):373-7. Czech.

PMID:
23078255
9.

Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.

Ticha I, Kleibl Z, Stribrna J, Kotlas J, Zimovjanova M, Mateju M, Zikan M, Pohlreich P.

Breast Cancer Res Treat. 2010 Nov;124(2):337-47. doi: 10.1007/s10549-010-0745-y. Epub 2010 Feb 5.

PMID:
20135348
10.

Comparative analysis of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in colorectal cancer and surrounding normal tissue.

Zimovjanova M, Sykora V, Novotny J, Gatek J, Petruzelka L, Holubec L, Pecen L.

Neoplasma. 2005;52(3):208-10.

PMID:
15875081
11.

4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.

Janku F, Pribylova O, Zimovjanova M, Pazdrova G, Safanda M, Zemanova M, Petruzelka L.

Bull Cancer. 2004 Oct 1;91(10):E279-83. Print 2004 Oct.

12.

Assessment of in vitro drug resistance of human breast cancer cells subcultured from biopsy specimens.

Krasna L, Netikova I, Chaloupkova A, Taislova E, Zimovjanova M, Vesely P, Danes J, Petruzelka L, Matouskova E.

Anticancer Res. 2003 May-Jun;23(3B):2593-9.

PMID:
12894546

Supplemental Content

Loading ...
Support Center